Agenda with Times

Look at the 2024 Agenda in PDF! 

Symposium Session Topics

Progress and challenges for targeting RNA in Oncology

Targeted new therapies

Cell Based Platforms and Immunotherapy

Patient Advocacy

Springboard for Starting Companies

Genomics and Computational Cancer Biology

Predictive Biomarkers for Patient Stratification and Response

New Trends in Cancer Research

Panel Discussion

Confirmed 2024 Talk Titles

Targeting RNA-processing vulnerabilities in pancreatic cancer

Corina Antal, PhD, Assistant Professor of Pharmacology, Moores Cancer Center, UC San Diego

Lilly Gateway Labs: A Novel Incubator Model in Support of the Biotech Ecosystem

Welcome Remarks

Joseph A. Califano III, MD, Director, Moores Cancer Center, Director, Glieberman Head and Neck Cancer Center, UC San Diego

Welcome Remarks

John Carethers, MD, Vice Chancellor for Health Sciences, UC San Diego

Panel Discussion

Ezra Cohen, MD, Chief Medical Officer for Oncology, Tempus Labs

Immune Suppressive Myeloid Cells in Regulation of Tumor Progression

Dmitry Gabrilovich, MD, PhD, Executive Director and Chief Scientist, Cancer Immunology, AstraZeneca

The PREDAPT Clinical Trial: Recent success in predicting the 25% of cancer patients benefiting from immunotherapy

Jarret Glasscock, PhD, Founder and CEO, Cofactor Genomics

Unraveling pancreatic cancer and its microenvironment: emerging therapeutics and discovery opportunities

Jacob R. Haling, PhD, Head, Cancer Therapeutics, Novartis Biomedical Research

Targeting PLK-1 in RAS mutated mCRC

Fairooz Kabbinavar, MD, FACS,Chief Medical Officer, Cardiff Oncology

Microbiome in Cancer Analysis and Treatment

Rob Knight, PhD, Director, Center for Microbiome Innovation, Professor of Pediatrics, Bioengineering, and Computer Science & Engineering, UC San Diego, Wolfe Family Endowed Chair in Microbiome Research, Rady Children’s Hospital

Development of a novel extrachromosomal DNA (ecDNA) diagnostic to support clinical development of ecDNA targeting therapeutics

Early Breast Cancer Detection with a Blood Test: Consequences for Therapeutic Development

Peter Kuhn, PhD, Dean’s Professor of Biological Sciences and Professor of Medicine, Biomedical Engineering, Aerospace & Mechanical Engineering, and Urology, USC

Patient Advocacy Presentation

Brian McCloskey, Patient Advocate and Co-Foundrr, Cancer Patient Lab

Panel Discussion

Mike Pellini, MD, Managing Partner, Section 32

Ubamatamab (MUC16xCD3 Bispecific Antibody): Phase 1 Clinical and Biomarker Results

Teresa Ramirez Montagut, MD, PhD, Executive Director, Oncology, Medical Affairs, Regeneron

Panel Discussion

Hunter Reed, MBA, Vice President - Science & Technology, Alexandria Venture Investments, Alexandria Real Estate Equities, Inc.

Strategies to Induce Tertiary Lymphoid Formation in Ovarian Cancer

David Schlaepfer, PhD, Professor, Department of Obstetrics, Gynecology, and, Reproductive Sciences, Moores Cancer Center, UC San Diego

Duane Roth Achievement Award Lecture: COVID Vaccine Meets CAR-T

Laura Shawver, PhD, President and Chief Executive Officer, Capstan Therapeutics

Modulating RNA Processing to Drug Oncogenic Transcription Factors

Peter Smith, PhD, Co-Founder, President & Chief Executive Officer, Remix Therapeutics

NanoEngineering Gone Viral: Plant Viruses Against Cancer

Nicole Steinmetz, PhD, Professor & Vice Chair, Dept. of NanoEngineering; Director of Nano-ImmunoEngineering; Co-Director, Center for Engineering in Cancer; Professor of Radiology & Bioengineering; Moores Cancer Center, San Diego Center for Precision Immunotherapy, Center for Drug Discovery & Innovation, UC San Diego

Myeloid Cells as Targets for Immune Therapy

Judith Varner, PhD, Professor of Medicine and Pathology, Moores Cancer Center, UC San Diego

Unlocking the Potential of Long Non-Coding RNA to Develop Transformative Medicines

Dominique Verhelle, PhD, Co-Founder, CEO & CSO, NextRNA Therapeutics

An Ex-vivo Organotypic Culture Platform of Mucinous Carcinomatosis Peritonei Identifies CDK4/6 Inhibition as a Novel Treatment

Jonathan Weitz, PhD, Postdoctoral Researcher, NCI Ruth Kirschstein Fellow, Moores Cancer Center, UC San Diego

Approaching the Allogeneic Tipping Point: P-BCMA-ALLO1 in Multiple Myeloma

Kristin Yarema, PhD, Poseida Therapeutics

Mapping Technologies to Understand RNA Processing

Gene Yeo, PhD, MBA, Professor of Cellular and Molecular Medicine, Founding Member, Institute for Genomic Medicine, Stem Cell Program, Moores Cancer Center, UC San Diego